8 completed, 3 terminated, 2 unknown, 1 withdrawn. 14 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 8, Terminated 3, Unknown 2, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Ileus: new trials by email Literature Review of Ileus trials Research Report on Ileus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection LB1148, Placebo - Ileus, Gastro-Intestinal Disorder | Phase 3 | Terminated | Palisade Bio | 23 | 2022-06-28 | 2024-06-13 |
| Efficacy of PRUcalopride in Critically Ill Patients With Paralytic ILeus Prucalopride, Placebo - Paralytic Ileus, Critically Ill | Phase 3 | Unknown | Prince of Songkla University | 62 | 2017-07-01 | 2020-02-06 |
| Alvimopan as Rescue in Post op Ileus Alvimopan, Control Group - Colorectal Surgery, Ileus | Phase 3 | Terminated | Sharon Stein | 14 | 2015-12-02 | 2022-11-18 |
| Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) DAM, Normal Saline - Postoperative Ileus | Phase 3 | Unknown | Beijing Bozhiyin T&S Co., Ltd. | 480 | 2013-04-01 | 2013-05-29 |
| Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) Eluxadoline, Placebo - Irritable Bowel Syndrome | Phase 3 | Completed | Furiex Pharmaceuticals, Inc | 1146 | 2012-05-29 | 2018-07-30 |
| Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian Cancer Gum chewing - Paralytic Ileus | Phase 2 / Phase 3 | Withdrawn | Chiang Mai University | 2011-07-01 | 2016-08-30 | |
| A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections Doripenem, Meropenem placebo, Meropenem - Abscess, Intra-Abdominal, Abdominal Abscess | Phase 3 | Terminated | Janssen Research & Development, LLC | 41 | 2010-12-01 | 2014-07-15 |
| The Effects of Gum Chewing on Bowel Function Recovery Following Cesarean Section Gum chewing - Paralytic Ileus | Phase 2 / Phase 3 | Completed | Chiang Mai University | 100 | 2010-05-01 | 2011-06-28 |
| A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair MOA-728, Placebo - Ileus | Phase 3 | Completed | Bausch Health Americas, Inc. | 374 | 2007-10-17 | 2019-09-04 |
| Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus alvimopan - Ileus | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 660 | 2004-06-01 | 2016-01-11 |
| Outcome of Palliative Management of Malignant Large Bowel Obstruction w/Colorectal Stents or Surgery Luminal stents, Minimally Invasive Surgical Bowel Diversion - Large Bowel Obstruction | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 180 | 2002-12-01 | 2007-12-10 |
| Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus Alvimopan - Ileus | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 510 | 2002-01-01 | 2015-07-20 |
| Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus Alvimopan - Ileus | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 666 | 2001-12-01 | 2015-07-20 |
| Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus Alvimopan - Ileus | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 451 | 2001-03-01 | 2017-08-22 |
Digestive System Diseases (3) · Intestinal Pseudo-Obstruction (3) · Colonic Pseudo-Obstruction (2) · Gastrointestinal Diseases (2) · Intestinal Diseases (2) · Abdomen, Acute (1) · Abdominal Abscess (1) · Abdominal Pain (1) · Appendicitis (1) · Colonic Diseases (1) · Colonic Diseases, Functional (1) · Critical Illness (1) · Diarrhea (1) · Hernia (1)
Intestinal Obstruction (13) · Gastrointestinal Diseases (12) · Intestinal Diseases (12) · Digestive System Diseases (11) · Pathological Conditions, Signs and Symptoms (4) · Intestinal Pseudo-Obstruction (2) · Signs and Symptoms (2) · Abscess (1) · Cecal Diseases (1) · Colonic Diseases (1) · Colonic Diseases, Functional (1) · Disease Attributes (1) · Gastroenteritis (1) · Intraabdominal Infections (1)
alvimopan (5) · Chewing Gum (2) · Amoxicillin-Potassium Clavulanate Combination (1) · Control Groups (1) · Doripenem (1) · Exercise (1) · Meropenem (1) · Saline Solution (1) · Solutions (1) · eluxadoline (1) · methylnaltrexone (1) · prucalopride (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (4) · Chiang Mai University (2) · Bausch Health Americas, Inc. (1) · Beijing Bozhiyin T&S Co., Ltd. (1) · Furiex Pharmaceuticals, Inc (1) · Janssen Research & Development, LLC (1) · Memorial Sloan Kettering Cancer Center (1) · Palisade Bio (1) · Prince of Songkla University (1) · Sharon Stein (1)
United States (10) · Thailand (3) · Canada (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Chile (1) · China (1) · Colombia (1) · Germany (1) · Hungary (1) · Italy (1) · Latvia (1) · Lithuania (1)
Kittipat Charoenkwan, MD (2) · Hans Gerdes, M.D. (1) · Lindsey Mathew (1) · Mitch Jones, MD (1) · Sawangpong Jandee, Dr. (1) · Sharon Stein, MD (1) · Ying-jiang Ye, professor (1)
PMID 20526599, PMID 15383800, PMID 15906123, PMID 16333556, PMID 19015469, PMID 26789872, PMID 28167156
2009 (1)